An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered Following Various Caloric Intakes As Compared To The Immediate Release Formulation.
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2015
At a glance
- Drugs Pregabalin (Primary)
- Indications Epilepsy; Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Postherpetic neuralgia; Postoperative pain; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Jul 2010 Actual number of patients added to 24 as reported by ClinicalTrials.gov.
- 06 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.